Driven By The Urgency Of Cancer Patients Who Need Effective Therapies
Our mission is to develop best-in-class and first-in-class precision medicines directed to specific oncogenic vulnerabilities in patients with limited treatment options.
A Focused Pipeline Portfolio
We have assembled a team with deep expertise in medicinal chemistry, cancer genetics and translational biology to accelerate the development and delivery of kinase inhibitor-based therapies.
